Treatment of dyslipidemia in the elderly

Journal of Geriatric Cardiology

Volumn 8, Issue 1, 2011, Pages 55-64

  Shao, Hong ^a   Chen, Li Quan ^a   Xu, Jun ^b  

^a QINGDAO MUNICIPAL HOSPITAL   (China)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; Dyslipidemia; Statins

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ACETYLSALICYLIC ACID; ATORVASTATIN; BEZAFIBRATE; BILE ACID SEQUESTRANT; CLOFIBRATE; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; CYCLOSPORIN; CYTOCHROME P450; ERYTHROMYCIN; EZETIMIBE; FARNESOL; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROLIDE; MEVALONIC ACID; NEFAZODONE; NICOTINIC ACID; PLACEBO; PRAVASTATIN; PROTEINASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN; WARFARIN;

ACANTHOSIS NIGRICANS; ADJUVANT THERAPY; AEROBIC EXERCISE; AGE; ATHEROSCLEROSIS; CARBOHYDRATE DIET; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; CONCENTRATION LOSS; CONJUNCTIVITIS; CONSTIPATION; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIARRHEA; DIET RESTRICTION; DIET THERAPY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DYSLIPIDEMIA; EPIGASTRIC FULLNESS; ERECTILE DYSFUNCTION; EXERCISE; FLATULENCE; FLUSHING; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENDER; GERIATRIC DISORDER; GERIATRIC PATIENT; GLOMERULOSCLEROSIS; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; ICHTHYOSIS; IMMOBILIZATION; INSOMNIA; KIDNEY DISEASE; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; LIVER NECROSIS; LIVER TOXICITY; MEDITERRANEAN DIET; MENOPAUSE; METABOLIC SYNDROME X; MICROALBUMINURIA; MORBIDITY; MORTALITY; MYOPATHY; MYOSITIS; NIGHTMARE; NOSE CONGESTION; OBESITY; PATIENT COMPLIANCE; PATIENT MONITORING; PREVALENCE; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SEX DIFFERENCE; SIDE EFFECT; SKIN IRRITATION; SLEEP DISORDER; SMOKING; STROKE; THROMBOEMBOLISM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 79953809941     PISSN: 16715411     EISSN: None     Source Type: Journal    
DOI: 10.3724/SP.J.1263.2011.00055     Document Type: Review

References (71)

1. China National Committee on Aging: Announcement (in Chinese) [on-line]. http://www.cnca.org.cn (accessed August 2010).
2. Moran A, Gu D, Zhao D, et al. Future cardiovascular disease in China: markov model and risk factor scenario projections from the coronary heart disease policy model-China. Circ Cardiovasc Qual Outcomes 2010; 3: 243-252.
3. Zhang XH, Lu ZL, Liu L. Coronary heart disease in China. Heart 2008; 94: 1126-1131.
4. Dalal D, Robbins J. Management of hyperlipidemia in the elderly population: an evidence-based approach. South Med J 2002; 95: 1255-1261. (Pubitemid 36109333)
5. Zhao WH, Zhang J, Zhai Y, et al. Blood lipid profile and prevalence of dyslipidemia in Chinese adults. Biomed Environ Sci 2007; 20: 329-335. (Pubitemid 47441813)
6. Hall KM, Luepker RV. Is hypercholesterolemia a risk factor and should it be treated in the elderly? Am J Health Promot 2000; 14: 347-356.
7. Deedwania PC. Hypercholesterolemia. Is lipid-lowering worthwhile for older patients? Geriatrics 2000; 55: 22-28.
8. Grundy SM, Cleeman JI, Rifkind BM, et al. Cholesterol lowering in the elderly population. Arch Intern Med 1999; 159: 1670-1678. (Pubitemid 29379128)
9. Ulrich S, Hingorani AD, Martin J, et al. What is the optimal age for starting lipid-lowering treatment? A mathematical model. BMJ 2000; 320: 1134-1140. (Pubitemid 30213976)
10. Benfante R, Reed D, Frank J. Do coronary heart diseas risk factors measured in the elderly have the same predictive roles as in the middle-aged. Comparisons of relative and attributable risks. Ann Epidemiol 1992; 2(3): 273-282.
11. Kuller L, Borhani N, Furberg C, et al. Prevalence of subclinical atherosclerosis and cardiovascular disease and association with risk factors in the Cardiovascular Health Study. Am J Epidemiol 1994; 139: 1164-1179. (Pubitemid 24184410)
12. Tuzcu EM, Kapadia SR, Tutar E, et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults. Circulation 2001; 103: 2705-2710. (Pubitemid 32538786)
13. Hunt D, Young P, Simes J, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial. Ann Intern Med 2001; 134: 931-940. (Pubitemid 32466232)
14. Kannel WB. Coronary heart disease risk factors in the elderly. Am J Geriatr Cardiol 2002; 11: 101-107. (Pubitemid 34614597)
15. Psaty BM, Anderson M, Kronmal RA, et al. The association between lipid levels and the risks of incident myocardial infarction, stroke, and total mortality: The Cardiovascular Health Study. J Am Geriatr Soc 2004; 52: 1639-1647. (Pubitemid 41709916)
16. Wenger NK. Dylipidemia as a risk factor at elderly age. Am J Geriatr Cardiol 2004; 13 (Suppl. 1): 4-9.
17. Pate R, Pratt M, Blair S, et al. Physical activity and public health. A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA 1995; 273: 402-407.
18. Lavie CJ. Treatment of hyperlipidemia in elderly persons with exercise training, nonpharmacologic therapy and drug combination. Am J Geriatr Cardiol 2004; 13 (3, Suppl. 1): 29-33.
19. Foster GD, Wyatt HR, Hill JO, et al. A randomized trial of a low carbohydrate diet for obesity. N Engl J Med 2003; 348: 2082-2090. (Pubitemid 36583303)
20. Shai I, Schwarzfuchs D, Henkin Y, et al. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med 2008; 359: 229-241. (Pubitemid 352008438)
21. Yancy WS Jr, Olsen MK, Guyton JR, et al. A low carbohydrate, ketogenic diet versus a low fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial. Ann Intern Med 2004; 140: 769-777.
22. Bravata DM, Sanders L, Huang J, et al. Efficacy and safety of low carbohydrate diets: a systemic review. JAMA 2003; 289: 1837-1850. (Pubitemid 37430255)
23. Merritt JC. Metabolic syndrome: soybean foods and serum lipids. J Natl Med Assoc 2004; 96: 1032-1041. (Pubitemid 38971096)
24. Aude YW, Mego P, Mehta J. Metabolic syndrome: dietary interventions. Curr Opin Cardiol 2004; 19: 453-459.
25. Knoops KT, de Groot LC, Kromhout D, et al. Meditarian diet, lifestyle factors, and 10-year mortality in elderly European men and women. The HALE project. JAMA 2004: 292: 1433-1439. (Pubitemid 39258335)
26. Ford ES, Giles WH, Dietz WH. Prevalence of metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359. (Pubitemid 34251969)
27. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2004; 285: 2486-2497.
28. Garcia-Palmiery M. Control of blood lipids in the elderly. Bol Asoc Med PR 2003; 95: 84-90.
29. Pedersen TR. Coronary artery disease: the Scandinavian Simvastatin Survival Study experience. Am J Cardiol 1998; 82: 53T-56T.
30. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-1009. (Pubitemid 26338729)
31. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
32. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosisi Prevention Study. JAMA 1998; 279: 1615-1622. (Pubitemid 28248586)
33. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. PROSPER study group. Prospective Study of Pravastatin in the Elderly at Risk. Lancet 2002; 360: 1623-1630.
34. Heart Protection Study Collaborative Group. MRC/BHF heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 23-33.
35. Sever PS, Dahlof B, Poulter NR, et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a multicenter randomised controlled trial. Lancet 2003; 361: 1129-1158.
36. Kastelein JJP, Bots ML. Statin therapy with ezetimibe or niacin in high-risk patients. N Engl J Med 2009; 361: 2180-2183.
37. Schwartz G, Olsson A, Ezekowitz M, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711-1718. (Pubitemid 32259905)
38. Ray JG, Mamdani M, Tsuyuki RT, et al. Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med. 2001; 161: 1405-1410. (Pubitemid 32681161)
39. Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia. Lancet 2000; 356: 1627-1631.
40. Yaffe K, Barrett-Connor E, Lin F, et al. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 2002; 59: 378-384. (Pubitemid 34208144)
41. Pasco JA, Kotowicz MA, Henry MJ, et al. Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. Arch Intern Med 2002; 162: 537-540. (Pubitemid 34193540)
42. Collins R, Armitage J, Parish S, et al. Effects of cholesterol lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363: 757-767.
43. Buemi M, Senatore M, Corica F, et al. Stains and progressive renal disease. Med Res Rev 2002; 22: 76-84.
44. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effects of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004; 57: 728-734. (Pubitemid 38901488)
45. Ose L, Davidson MH, Stein EA, et al. Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hepercholesterolemia. Worldwide Expanded Dose Simvastatin Study Group. Clin Cardiol 2000; 23: 39-46. (Pubitemid 30053469)
46. Gaist D, Rodriguez LA, Huerta C. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 2001; 12: 565-569. (Pubitemid 32761999)
47. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol 2003; 92: 152-160. (Pubitemid 36835963)
48. Farmer JA, Torre-Amione G. Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Saf 2000; 23: 197-213.
49. Scott R, O'Brien R, Fulcher G, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009; 32: 493-498.
50. Farmer JA. Handbook of Cholesterol Management; Science Press: Marrickville, Austrilia, 2004; 74-75.
51. Neve BP, Fruchart JC, Staels B. Role of the peroxisome proliferatior-activated receptors (PRAR) in atherosclerosis. Biochem Pharmacol 2000; 60: 1245-1250.
52. MacIsaac R, Jerums G. Treatment of dyslipidemia in the elderly. J Pharm Prac Res 2002; 32: 188-193.
53. nd Edition; Handbooks in Healthcare: Newtown, PA, United States, 2001.
54. Knapp RH. Drug treatment of lipid disorders. N Engl J Med 1999; 341: 498-511.
55. Arnos WS. Pharmacologic therapy of lipid disorders in the elderly. Am J Geriatr Cardiol 2002; 11: 247-256.
56. A cooperative trial in the primary prevention of ischeamic heart disease using clofibrate. Report from the Committee of Principal Investigators. Br Heart J 1978; 40: 1069-1118.
57. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-1245. (Pubitemid 17147964)
58. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000; 102: 21-27.
59. Robins HB Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410-418. (Pubitemid 29362514)
60. Chapman MJ, Assmann G, Fruchart JC, et al. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid-a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004; 20: 1253-1268. (Pubitemid 39120790)
61. Danish J, Collins R, Peto R. Lipoprotein (a) and coronary heart disease: meta-analysis of prospective studies. Circulation 2000; 102: 1082-1085.
62. Bays HE, McGovern ME. Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution, than atorvastatin and simvastatin. Prev Cardiol 2003; 6: 179-188. (Pubitemid 37386151)
63. Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiople Intervention Trial. JAMA 2000; 284: 1263-1270 .
64. Parra JL, Reddy KR. Hepatotoxicity of hypolipidemic drugs. Clin Liver Dis 2003; 7: 415-433 . (Pubitemid 36807740)
65. Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358: 1431-1443. (Pubitemid 351482735)
66. Simons L, Tonkon M, Masana L, et al. Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemia patients with diabetes mellitus or metabolic syndrome. Curr Med Res Opin 2004; 20: 1437-1445. (Pubitemid 39361347)
67. Ballantyne CM, Houri J, Notarbartolo A, et al. Effects of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 107: 2409-2415. (Pubitemid 36605221)
68. Sager PT, Melani L, Lipka L, et al. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol 2003; 92: 1414-1418. (Pubitemid 37532562)
69. Prosser LA, Stinnett AA, Goldman PA, et al. Cost- effectiveness of cholesterol-lowering therapies according to selected patients' characteristics. Ann Intern Med 2000; 132: 769-779. (Pubitemid 30317791)
70. Ganz DA, Kuntz KM, Jacobson GA, et al. Cost-effectiveness of 3-hydrosy-3-methylglutary coenzyme A reductase inhibitor therapy in older patients with myocardial infarction. Ann Intern Med 2000; 132: 780-787. (Pubitemid 30317792)
71. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid-lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504. (Pubitemid 38477774)